Mark McClellan, M.D., Ph.D., discusses the latest COVID variant arcturus, and its growing presence in ... and Prevention Director Mandy Cohen explains why another new round of COVID-19 shots is ...
An infectious diseases expert breaks down four myths about COVID-19 vaccines and masking. 0:48 Mark McClellan, M.D., Ph.D., discusses the latest COVID variant arcturus, and its growing presence in the ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
H.C. Wainwright's analyst highlighted the anticipation for early commercial results from Kostaive, Arcturus' COVID-19 vaccine marketed in Japan by Meiji Seika Pharma, a subsidiary of Meiji ...
H.C. Wainwright's analyst highlighted the anticipation for early commercial results from Kostaive, Arcturus' COVID-19 vaccine marketed in Japan by Meiji Seika Pharma, a subsidiary of Meiji Holdings ...
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...
potential regulatory developments in Japan for their COVID-19 treatment Kostaive, along with existing orders, signify a strong revenue stream. Collectively, these elements underscore Arcturus ...
Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...
No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to become dominant in the autumn of 2024, the early signs were ominous. The latest descendant of ...
As new COVID-19 variants emerge, recognizing symptoms and not dismissing them as common colds is crucial. Symptoms include fever, cough, and loss of taste or smell. Testing is key to identifying ...